N-glycosylation engineering in chimeric antigen receptor T cells enhances anti-tumor activity
De Bousser, E.; Festjens, N.; Meuris, L.; Plets, E.; Van Hecke, A.; Wyseure, E.; De Munter, S.; Vandekerckhove, B.; Callewaert, N.
Show abstract
Chimeric antigen receptor (CAR) T cell therapy has had limited success in solid tumors, requiring novel enhancement strategies. Modifying the glycocalyx of CAR T cells is unexplored; we report on genome-editing of the MGAT5 gene to abolish human CAR T N-glycan poly-LacNAc modifications. This boosted tumor control in carcinoma and lymphoma models, for donors of whom the non-engineered CAR T cells largely failed in tumor control. More blood-circulating MGAT5 KO CD70 nanoCAR T cells were found, exhibiting potent tumor cell-killing activity ex vivo, while non-glycoengineered CAR T cells faltered. MGAT5 KO CD70 nanoCAR T cells also mediated durable anti-tumor immunity, improving control of secondary carcinoma challenge months later. Single-cell transcriptomics revealed increased mitotic activity and type I interferon signaling, indicating sustained intratumoral activation. The glyco-engineered cells had unaltered antigen sensitivity and dependence on T cell growth factors, preserving key safety features. MGAT5 KO is readily compatible with clinical manufacturing, representing a promising approach to enhance CAR T cell therapy.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 95%
- GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma 95%
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 95%
Similar papers in this journal
- Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs 94%
- A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) 94%
- GFAP splice variants fine-tune glioma cell invasion and tumour dynamics by modulating migration persistence 94%
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 96%
- Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses 95%
- Combining an alarmin HMGN1 peptide with PD-L1 blockade facilitates stem-like CD8+ T cell expansion and results in robust antitumor effects 94%
Similar papers in this journal
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting 96%
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy 95%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 95%
Similar papers in this journal
- Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2 95%
- T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H 94%
- Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.